Smurfit Kappa Group Free cash flow decreased by 168.6% to -$420.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 73.6%, from -$242.00M to -$420.00M. Over 2 years (FY 2022 to FY 2025), Free cash flow shows an upward trend with a 54.5% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $125.75M | $125.75M | $125.75M | $125.75M | $343.00M | -$166.00M | $163.00M | -$192.00M | $212.00M | -$242.00M | $307.00M | $523.00M | $612.00M | -$420.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +172.8% | -148.4% | +198.2% | -217.8% | +210.4% | -214.2% | +226.9% | +70.4% | +17.0% | -168.6% |
| YoY Change | — | — | — | — | +172.8% | — | — | — | -38.2% | -45.8% | +88.3% | +372.4% | +188.7% | -73.6% |